On Monday, Neuronetics Inc. (NASDAQ:STIM), a provider of noninvasive treatments for psychiatric disorders, agreed to acquire Greenbrook TMS Inc. (OTC:GBNHF) in an all-stock transaction. In fiscal year 2023, the combined company’s pro forma revenue would have been approximately $145 million, effectively doubling the scale of the stand-alone businesses. Additionally, the combined company expects mid-teens year-over-year revenue growth in fiscal years 2025 and 2026. Through optimizing marketing spend and back office functions, the combined company expects to realize at least $15 million of annualized cost savings, most of which will be realized in fiscal year 2025. Due to expected revenue growth and the realization of cost synergies, the combined company anticipates being Adjusted EBITDA positive and cash flow positive for the full fiscal year 2025, excluding one-time costs related to the transaction. Neuronetics’ executive management team will continue with the combined company. Following the ...